AMAZENTIS
23.1.2020 21:58:10 CET | Business Wire | Press release
Amazentis announces the debut of Timeline , a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study , there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/
Timeline contains the proprietary nutrient Mitopure ™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants of our cells.
Timeline will be the first consumer product in the world to contain precisely calibrated doses of Mitopure that have been clinically shown to improve the mitochondrial and cellular health of the skeletal muscle. Timeline will be available to purchase online for consumers in the United States in the first half of 2020 at www.timelinenutrition.com .
“After a decade of research and trials to perfect Mitopure, we’re giving consumers access to a product that improves their muscle health by targeting aging mitochondria,” said Amazentis CEO and Co-Founder, Chris Rinsch.
“For years, consumers have been searching for a solution to maintain muscle health as they age; Timeline provides a new way to proactively take control of cellular health early on, which directly impacts the aging process,” added Amazentis Co-Founder and Chairman Patrick Aebischer.
The World Economic Forum engages societal leaders to shape global, regional and industry agendas. As part of the Forum, there will be a panel discussion on January 23rd at 15:00 CET at the House of Switzerland, focusing on the innovations in the food and nutrition industry. During the conversation, Rinsch will share the health benefits of Timeline and Mitopure with the audience. The panel will be moderated by CNN Money Switzerland Anchor Anna Maria Montero and include:
- Nestlé Global Chairman of the Board, Paul Bulcke
- École Polytechnique Fédérale de Lausanne (EPFL) President, Martin Vetterli
- 3 Star Michelin Chef, Hôtel de Ville de Crissier, Franck Giovannini
- Amazentis CEO and Co-Founder, Chris Rinsch
Amazentis is an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions linked to aging. The company’s lead ingredient, Mitopure™, has been favorably reviewed by the U.S. Food and Drug Administration (FDA) following a GRAS (generally recognized as safe) filing. Mitopure has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation.
About Timeline
Timeline is a novel nutrition brand developed by Amazentis on the belief that uncompromising research can unlock a new class of nutrition that is backed by cutting edge science. As scientists, we know that physical decline from aging can’t be stopped. However, through its groundbreaking science, Timeline is committed to developing products designed to help reduce the impact of time on health. For more information, please visit timelinenutrition.com
.
About Mitopure
Mitopure is a highly pure form of Urolithin A, a bioactive dietary metabolite that is naturally produced when eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, leading to the growth of healthy mitochondria. For more information, please visit https://www.mitopure.com/
.
About Amazentis
Amazentis is an innovative life science company that employs today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. For more information on Amazentis, please visit www.amazentis.com
.
Related Links
https://www.timelinenutrition.com
https://www.mitopure.com
https://www.amazentis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005820/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global udvider sin juridiske virksomhed i Pakistan med et nyt medlemsfirma2.10.2026 22:36:00 CEST | Pressemeddelelse
Andersen Global styrker sin juridiske tilstedeværelse i Pakistan, idet Samdani & Qureshi, der har været samarbejdspartner siden 2021, skifter navn til Andersen Legal in Pakistan og bliver den seneste medlemsvirksomhed, der slutter sig til organisationen. Andersen Legal in Pakistan har hovedkontor i Islamabad og rådgiver både indenlandske og internationale klienter, herunder virksomheder, investorer, finansielle institutioner, offentlige enheder, udviklingsorganisationer og privatpersoner, om juridiske, kommercielle og regulatoriske forhold. Firmaet arbejder også med voldgift og tvistbilæggelse og rådgiver om komplekse transaktioner, investeringer, finansiering, projekter og tvister i Pakistan og på tværs af landegrænser. "Vores tilgang bygger på stærkt engagement fra ledelsen, klar kommunikation og disciplineret analyse med fokus på at levere rådgivning, som vores klienter kan omsætte til handling," sagde Nudrat Ejaz Piracha, partner hos Andersen Legal in Pakistan. "Ved at blive en del
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press release
Appointments expand emnify executive team to accelerate global growth emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press release
Enterprise software veteran to lead Tacton’s united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release
Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom